This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Luzitin, S.a., Universidade De Coimbra. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2019
Title: Luis Gabriel Borges Rocha: Innovator in Photodynamic Therapy
Introduction
Luis Gabriel Borges Rocha is a notable inventor based in Coimbra, Portugal. He has made significant contributions to the field of photodynamic therapy through his innovative research and development of new pharmaceutical compositions.
Latest Patents
Luis Gabriel Borges Rocha holds a patent for "Low molecular weight derivatives of carboxamide halogenated porphyrins, namely chlorins and bacteriochlorins, and their applications thereof." This invention relates to carboxamide halogenated porphyrin derivatives, particularly bacteriochlorin or chlorin, which are utilized in photodynamic therapy. The derivatives are capable of detecting and treating hyperproliferative disorders when exposed to adequate lighting. The patent also describes a pharmaceutical composition that includes these derivatives for the treatment of cancer and various infections in humans or animals. He has 1 patent to his name.
Career Highlights
Throughout his career, Luis Gabriel Borges Rocha has worked with prominent organizations such as Luzitin, S.A. and Universidade de Coimbra. His work has focused on advancing medical treatments and improving patient outcomes through innovative solutions.
Collaborations
Luis has collaborated with notable colleagues, including Goncalo Pereira Nascimento Costa and Nuno Paulo Ferreira Goncalves. Their combined expertise has contributed to the success of his research and inventions.
Conclusion
Luis Gabriel Borges Rocha is a distinguished inventor whose work in photodynamic therapy has the potential to revolutionize treatment options for various medical conditions. His innovative approach and dedication to research continue to make a significant impact in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile